Evidence map›Paper›PMID 42332332›Full record

ArticleCellular and molecular life sciences : CMLS2026

Interaction between CD82 and integrin αVβ3 selectively regulates collective movement of tumor cells via endolysosomal trafficking.

Xue Jun Wang, Mekel M Richardson, Yingjun Ding, Chao Jiang, Songlan Liu, Bin Zhou, Shuping Li, Junxiong Chen, Eric Rubinstein, Franklin A Hays and 2 more

Abstract read
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xue Jun WangUniversity of Oklahoma Health Science Center, BRC1474, 975 NE 10th Street, Oklahoma City, OK, 73104, USA.
Mekel M Richardson *University of Oklahoma Health Science Center, BRC1474, 975 NE 10th Street, Oklahoma City, OK, 73104, USA.
Yingjun Ding *University of Oklahoma Health Science Center, BRC1474, 975 NE 10th Street, Oklahoma City, OK, 73104, USA.
Chao JiangUniversity of Oklahoma Health Science Center, BRC1474, 975 NE 10th Street, Oklahoma City, OK, 73104, USA.
Songlan LiuUniversity of Oklahoma Health Science Center, BRC1474, 975 NE 10th Street, Oklahoma City, OK, 73104, USA.
Bin ZhouUniversity of Tennessee Health Science Center, Memphis, TN, 38163, USA.
Shuping LiUniversity of Oklahoma Health Science Center, BRC1474, 975 NE 10th Street, Oklahoma City, OK, 73104, USA.
Junxiong ChenUniversity of Oklahoma Health Science Center, BRC1474, 975 NE 10th Street, Oklahoma City, OK, 73104, USA.
Eric RubinsteinSorbonne Université, Inserm, CNRS, Centre d'Immunologie Et Des Maladies Infectieuses, CIMI-Paris, Paris, 75013, France.
Franklin A HaysUniversity of Oklahoma Health Science Center, BRC1474, 975 NE 10th Street, Oklahoma City, OK, 73104, USA.
Kamiya MehlaUniversity of Oklahoma Health Science Center, BRC1474, 975 NE 10th Street, Oklahoma City, OK, 73104, USA.
Xin A ZhangUniversity of Oklahoma Health Science Center, BRC1474, 975 NE 10th Street, Oklahoma City, OK, 73104, USA. xin-zhang-1@ouhsc.edu.ORCID http://orcid.org/0000-0001-5074-3847

Funding

Molecular Mmechanism of KAI1/CD82-mediated SuppressionR01CA096991 · NCI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI ZHANG, XIN A · 2004 to 2014
$2.8M
Tetraspanin-enriched microdomains and endothelial barrier functionR01HL132553 · NHLBI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI ZHANG, XIN A · 2017 to 2020
$1.5M
Foundation for the National Institutes of Health CA096991Foundation for the National Institutes of Health HL132553NCI NIH HHS R01 CA096991NHLBI NIH HHS R01 HL132553
6 · The paper itself

Abstract

Tetraspanin CD82/KAI1 inhibits cell movement and metastasis of malignant tumors, and reduced and lost expressions of CD82 predict worse outcomes of patients with malignant tumors. Here we found that CD82 inhibits both solitary and collective movement of tumor cells. The CD82 YVAA mutation, which affects CD82 trafficking, selectively abrogates CD82-mediated inhibition of collective migration. Cilengitide, at the concentration that specifically inhibits integrin αVβ3, also selectively blocks collective movement, underscoring a promotive role of integrin αVβ3 in this mode of cell motility. In contrast, integrin αVβ5 appears non-essential for collective migration, and both αVβ3 and αVβ5 are dispensable for solitary movement on fibronectin, highlighting distinct functions of different integrins in different modes of tumor cell movement. CD82 interacts with αVβ3 and αVβ5 integrins and downregulates their protein levels, while CD82 YVAA mutation relinquishes this downregulation without disrupting CD82 interactions with these integrins. Mechanistically, CD82, but not the YVAA mutant, considerably reduces digitation junction-the structure where integrin αVβ3 localizes-and likely directs integrin αVβ3 for lysosomal degradation, thereby lowering its level and suppressing collective migration. Thus, our study reveals that i) integrin αVβ3 promotes collective movement of tumor cells, ii) CD82 counteracts this by diminishing integrin αVβ3 and its presence in microextrusions, and iii) digitation junction likely participates in collective cell movement. Our study further demonstrates that endolysosomal trafficking of CD82 and integrin αVβ3 is needed for their collective movement-regulatory activities and that coupling of metastasis suppressor CD82/KAI1 with different partners regulates different modes of cell movement.

Indexed as

Cell MovementEndosomesIntegrin alphaVbeta3Kangai-1 ProteinLysosomesAnimalsCell Line, TumorHumansMutationProtein BindingProtein TransportReceptors, VitronectinSnake VenomsCD82 protein, humanCilengitideIntegrin alphaVbeta3integrin alphaVbeta5Kangai-1 ProteinReceptors, VitronectinSnake VenomsCilengitideDigitation junctionMicroextrusionProstate cancerSolitary movementTetraspanin

Identifiers

PMID42332332
PMCPMC13547200

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.